Incomum · Saberes
Tirbanibulin
Chemical compound
Tirbanibulin, sold under the brand name Klisyri, is a medication used for the treatment of actinic keratosis (AK) on the face or scalp. It functions by inhibiting both tubulin polymerization and Src kinase signaling. It is potentially effective in impeding the development of squamous cell carcinoma in situ.
Na Wikipédia
Texto em inglês Ainda não há artigo no seu idioma: trecho em inglês.
Tirbanibulin, sold under the brand name Klisyri, is a medication used for the treatment of actinic keratosis (AK) on the face or scalp. It functions by inhibiting both tubulin polymerization and Src kinase signaling. It is potentially effective in impeding the development of squamous cell carcinoma in situ. The most common side effects include local skin reactions, application site pruritus, and application site pain. Tirbanibulin was approved for medical use in the United States in December 2020, and in the European Union in July 2021. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Texto: Wikipédia em inglês, CC BY-SA 4.0. · Imagem: Vaccinationist (Public domain) ·